- Diversity & Inclusion
Contract GP +3% LFL
Perm GP -15% LFL in line with average headcount
Group GP -6% LFL
Pharma & Biotech and Energy & Engineering represent 36% of GP
Non UK + I GP 68% of total
Net cash: £15.5m.
Source: Half Year Results ended 26 May 2013
Gary Elden, CEO, commented: "Against a backdrop of weaker macroeconomic conditions, we had a satisfactory first half. Contract, international and expansion of our newer sectors remained our strategic priorities in the period, along with a refocusing of elements of the business to ensure they are positioned to target growth markets more effectively..."